Oragenics Inc. Secures HREC Approval and Advances Toward Phase IIa Clinical Trials for Pioneering Concussion Treatment

Reuters08-11

<a href="https://laohu8.com/S/OGEN">Oragenics Inc.</a> Secures HREC Approval and Advances Toward Phase IIa Clinical Trials for Pioneering Concussion Treatment

Oragenics Inc. has announced key regulatory progress in its pursuit to advance its lead candidate, ONP-002, aimed at becoming the first FDA-approved pharmacological treatment for concussion. During the second quarter of 2025, the company secured Human Research Ethics Committee (HREC) approval in Australia, marking a significant milestone in their clinical development. Additionally, Oragenics has finalized a US-based cGMP manufacturing agreement with Sterling Pharma Solutions, ensuring reliable, scalable production to support successful clinical execution and future commercial readiness. These strategic advancements are part of Oragenics' broader mission to revolutionize neurotrauma care through its pioneering brain-targeted therapeutics and proprietary intranasal delivery technology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oragenics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-022908), on August 11, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2558668340?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-11 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558668340","market":"fut","top_or_hot":-1,"title":"Oragenics Inc. Secures HREC Approval and Advances Toward Phase IIa Clinical Trials for Pioneering Concussion Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OGEN\">Oragenics Inc.</a> Secures HREC Approval and Advances Toward Phase IIa Clinical Trials for Pioneering Concussion Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Oragenics Inc. has announced key regulatory progress in its pursuit to advance its lead candidate, ONP-002, aimed at becoming the first FDA-approved pharmacological treatment for concussion. During the second quarter of 2025, the company secured Human Research Ethics Committee (HREC) approval in Australia, marking a significant milestone in their clinical development. Additionally, Oragenics has finalized a US-based cGMP manufacturing agreement with Sterling Pharma Solutions, ensuring reliable, scalable production to support successful clinical execution and future commercial readiness. These strategic advancements are part of Oragenics' broader mission to revolutionize neurotrauma care through its pioneering brain-targeted therapeutics and proprietary intranasal delivery technology.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oragenics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-022908), on August 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oragenics Inc. Secures HREC Approval and Advances Toward Phase IIa Clinical Trials for Pioneering Concussion Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOragenics Inc. Secures HREC Approval and Advances Toward Phase IIa Clinical Trials for Pioneering Concussion Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-11 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OGEN\">Oragenics Inc.</a> Secures HREC Approval and Advances Toward Phase IIa Clinical Trials for Pioneering Concussion Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Oragenics Inc. has announced key regulatory progress in its pursuit to advance its lead candidate, ONP-002, aimed at becoming the first FDA-approved pharmacological treatment for concussion. During the second quarter of 2025, the company secured Human Research Ethics Committee (HREC) approval in Australia, marking a significant milestone in their clinical development. Additionally, Oragenics has finalized a US-based cGMP manufacturing agreement with Sterling Pharma Solutions, ensuring reliable, scalable production to support successful clinical execution and future commercial readiness. These strategic advancements are part of Oragenics' broader mission to revolutionize neurotrauma care through its pioneering brain-targeted therapeutics and proprietary intranasal delivery technology.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oragenics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-022908), on August 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nNDLZt0y5:1","article_id":"2558668340","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558668340","pubTimestamp":1754915499,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Oragenics Inc. has announced key regulatory progress in its pursuit to advance its lead candidate, ONP-002, aimed at becoming the first FDA-approved pharmacological treatment for concussion. During the second quarter of 2025, the company secured Human Research Ethics Committee  approval in Australia, marking a significant milestone in their clinical development. Additionally, Oragenics has finalized a US-based cGMP manufacturing agreement with Sterling Pharma Solutions, ensuring reliable, scalable production to support successful clinical execution and future commercial readiness. These strategic advancements are part of Oragenics' broader mission to revolutionize neurotrauma care through its pioneering brain-targeted therapeutics and proprietary intranasal delivery technology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informatio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","OGEN":"Oragenics Inc."},"translate_title":"Oragenics Inc.获得HREC批准并推进开创性脑震荡治疗的IIa期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OGEN":0.9},"content_text":"Oragenics Inc. Secures HREC Approval and Advances Toward Phase IIa Clinical Trials for Pioneering Concussion Treatment\n    \n\n        Oragenics Inc. has announced key regulatory progress in its pursuit to advance its lead candidate, ONP-002, aimed at becoming the first FDA-approved pharmacological treatment for concussion. During the second quarter of 2025, the company secured Human Research Ethics Committee (HREC) approval in Australia, marking a significant milestone in their clinical development. Additionally, Oragenics has finalized a US-based cGMP manufacturing agreement with Sterling Pharma Solutions, ensuring reliable, scalable production to support successful clinical execution and future commercial readiness. These strategic advancements are part of Oragenics' broader mission to revolutionize neurotrauma care through its pioneering brain-targeted therapeutics and proprietary intranasal delivery technology.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oragenics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-022908), on August 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2558668340","isCrawlerRequest":true}